Dear readers,
We wish all visitors to our news page a peaceful and healthy New Year and a successful start to the New Year. Stay healthy! We will be back with the latest news from 4 January.
Best regards
Your editorial team of European Biotechnology Magazine
Following a rapid FDA approval, the European drug authority EMA has recommended to conditionally approve BioNTechs mRNA vaccine BNT162b2 in the EU.
Only two and a half months after its launch, the EU bioecocomy venture capital fund ECBF has doubled the volume of its first closing.
Danish Novo Holdings has founded Hemab ApS that is focussed on fighting orphan bleeding disorders by bi-specific antibodies.
Austria has needed a biotech association for a long time. In just two months, entrepreneurs have launched Biotech Austria.
Weathered microplastic particles may pose a greater risk than pristine ones, suggests a study of German researchers on mouse cells.
Diagnostics developer Centogene NV and Alnylam Pharmaceuticals launched a clinical programme aimed at improving ATTRv diagnosis.
Green chemistry company Avantium NV has secured a €7.5m funding from the National Programme Groningen to support the construction of a 5 kilotonnes FDCA plant.
Biontech and Pfizer have received emergency approval for their COVID-19 vaccine in the UK. Mass immunization could start next week, the first in Western countries.